about
Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosusPrimary cardiac disease in systemic lupus erythematosus patients: protective and risk factors--data from a multi-ethnic Latin American cohort.Early discoid lupus erythematosus protects against renal disease in patients with systemic lupus erythematosus: longitudinal data from a large Latin American cohort.Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort.Trends in dermatomyositis- and polymyositis-related mortality in the state of São Paulo, Brazil, 1985-2007: multiple cause-of-death analysis.IL-2, IL-5, TNF-α and IFN-γ mRNA expression in epidermal keratinocytes of systemic lupus erythematosus skin lesionsHigh mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statinsHigh prevalence of vertebral deformity in premenopausal systemic lupus erythematosus patients.Lupus in Latin-American patients: lessons from the GLADEL cohort.Predictive factors of flares in systemic lupus erythematosus patients: data from a multiethnic Latin American cohort.Estimating the incidence of systemic lupus erythematosus in a tropical region (Natal, Brazil).Leflunomide in Takayasu arteritis - A long term observational study.Brazilian urban population norms derived from the health-related quality of life SF-6D.Prevalence of musculoskeletal symptoms in the five urban regions of Brazil-the Brazilian COPCORD study (BRAZCO).A Study of Multiple Causes of Death in Rheumatoid Arthritis.Visual loss resulting from immunosuppressive therapy in patients with syphilitic uveitis.[Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis].Evaluation of functional capacity in individuals with signs and symptoms of musculoskeletal disease: results of the BRAZCO population study (Brazilian COPCORD Study).Long-term persistence of anti-β2 glycoprotein I in treated leprosy patients.Controlled trial with chloroquine diphosphate in systemic lupus erythematosus.Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus.Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases.Supervised physical exercise improves endothelial function in patients with systemic lupus erythematosus.The effect of acute physical exercise on cytokine levels in patients with systemic lupus erythematosus.Factors predictive of high disease activity early in the course of SLE in patients from a Latin-American cohort.Impact of hypertension and hyperhomocysteinemia on arterial thrombosis in primary antiphospholipid syndrome.The Influence of Income and Formal Education on Damage in Brazilian Patients With Systemic Lupus Erythematosus.Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL).Therapeutic Guidelines for Latin American Lupus Patients: Methodology.Increased myeloperoxidase plasma levels in rheumatoid arthritis.Oral microbial colonization in patients with systemic lupus erythematous: correlation with treatment and disease activityFirst Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of RheumatologSystemic lupus erythematosus in São Paulo/Brazil: a clinical and laboratory overviewA controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritisC2 deficiency in blood donors and lupus patients: prevalence, clinical characteristics and HLA-associations in the Brazilian populationTakayasu arteritis. Treatment and prognosis in a university center in BrazilSystemic vasculitis: a difficult diagnosisScleroderma-like nailfold capillaroscopic abnormalities are associated with anti-U1-RNP antibodies and Raynaud's phenomenon in SLE patientsAtorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trialVitamin D deficiency in patients with active systemic lupus erythematosus
P50
Q28275253-1E57D660-80DA-4D60-BA7B-3315CEEEDDE5Q30778909-0E6CFB30-8A9C-41F1-8A2C-1DFC6EF95868Q31102783-628BFB96-35C8-41C1-82E6-C418A3183363Q33529416-441B0CF9-76E8-4F34-8C62-9E5ECB984586Q33715014-E41D1934-F66C-4F00-9A54-8432BAFDA42AQ34604047-21D0AF7D-7F78-4453-A432-7F38EDCD6BB8Q35782029-FA4E8C6F-A58F-43C1-985A-D820FA6B3F8BQ36244355-3E6E9E18-9209-49FE-8DF2-47C9F42ACB27Q38362113-64913249-F33B-4E63-A9B4-C42C7D12C577Q38600390-9ACCA3E5-435A-4927-8044-98E8438B1A1AQ39560849-6A86A493-6FA0-4030-8A96-107F185732A1Q39961951-78F29331-2CAF-4AE1-8072-81B34E244EFDQ40274086-933E8DA9-0588-40ED-8991-0619C1EE0451Q40279365-8A92DE91-6390-406C-A602-970ADCEAC889Q40425932-D8F1C094-F283-4601-AF6D-C62AEDD0A35DQ41084188-D085674C-8140-42FB-B168-B2E888122004Q41540102-83D2FD6E-727F-417C-8A9C-5F43F35592F0Q41685488-D63470FB-2CD4-49C2-ABFC-8DA84C443046Q41736522-E66D1583-D2EC-4EF5-B7C3-FA21FEA8C92CQ41930670-0F441921-4DDA-474F-AAA2-ACFBEBA7041BQ43089915-65637883-591D-494A-947E-3ED48553F347Q43717482-DC3C7032-60CE-4E86-AEBB-0A6C5F2C2E6FQ44897123-E19BC081-4E86-4AFB-82DD-67CC327DB7BFQ46268061-13462B69-36D3-44D2-9328-5D3EF4FDD379Q46335432-0CD42230-C15D-435F-8014-300EAFF23116Q46982104-85833403-A5F3-4AC9-9CC2-AEBC32B1617CQ47701185-1F5CB8EE-F2E2-4DDD-BF39-9BA02532ACD6Q47938542-E2CD4D2C-9464-4E8E-A543-0EDA166514DFQ50099729-77E19266-84E6-4F70-98C0-2D2DA3BCAC4DQ51503196-88B92B22-13D2-46DF-BBB8-6CB05F12984BQ60809342-40808A6C-C6A6-4418-BD87-74BA0E224275Q64924819-807463A7-0446-49D8-89DD-30E72C986AD2Q72345758-2CD2BD30-5944-46A8-92E8-29A894CD7C08Q72702799-D9037041-990D-4019-9CE2-C07A750EF0A6Q73523764-CB114F9F-AE8F-45BA-A0D0-FE4D407F36FCQ74297362-546A762A-BFDE-4B09-A5C1-511F3ECFFB12Q74416421-A30E8C76-B793-4879-A6CD-7BA881549057Q77783206-2A65FE1B-1C7E-4343-97A5-248276EA52C1Q80784895-7A09ACF3-D720-4917-B8E8-E8B6574C35D3Q81577955-4A74C8CA-B73F-4B18-B3C3-074D2E40B878
P50
description
researcher
@en
wetenschapper
@nl
name
E I Sato
@en
E I Sato
@nl
type
label
E I Sato
@en
E I Sato
@nl
prefLabel
E I Sato
@en
E I Sato
@nl
P106
P31
P496
0000-0001-8540-014X